Extended Data Fig. 1: LNPs delivering siRab27a and mSTING-miR-122 do not induce systemic toxicity.
From: Tumour-derived small extracellular vesicles act as a barrier to therapeutic nanoparticle delivery
1x106 MC38 cells were s.c. injected into the right flank of mice at day 0. At day 8, the tumour size reached 50 mm3. Mice were then treated with the following LNPs: 1) LNP co-encapsulating siRab27a and scrambled mRNA; 2) LNP co-encapsulating scrambled siRNA and mSTING-miR-122; or 3) LNP co-encapsulating siRab27a and mSTING-miR-122. These LNPs were i.v. injected (0.25mg/kg) into mice at days 7, 9, 11, 13, and 15. PBS injections into mice at different time points were used as a control group. When tumour sizes in the PBS group reached 1500 mm3 (day 20), mice were euthanized and ALT (a), AST (b), IL-6 (c), and IL-12p70 (d) in mouse blood were measured. e, H&E staining of mouse livers collected from different groups. f, H&E staining of major mouse organs collected from the PBS group and the STING-miR-122 + siRab27a group at day 50. Data in a-d was shown as mean ± s.d. (n=5 biologically independent samples). One-way ANOVA was used to determine statistical differences. e and f, Experiments were repeated independently 3 times with similar results.
